About
Seth Ettenberg, Ph.D., is President and CEO of BlueRock Therapeutics, where he previously served as Chief Scientific Officer from 2020 to 2021. Before BlueRock, he was a founding member and Chief Scientific Officer of Unum Therapeutics, and earlier led the Cambridge site of Novartis Oncology Biotherapeutics. He also serves as an independent board member at Kano Therapeutics and on the 2026 Board of Directors of the Alliance for Regenerative Medicine.
Areas of interest
biotechcell therapygene therapyregenerative medicineoncologydrug development